437 related articles for article (PubMed ID: 16715137)
1. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
2. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
3. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
Fan F; Feng L; He J; Wang X; Jiang X; Zhang Y; Wang Z; Chen Y
Carcinogenesis; 2008 Jun; 29(6):1157-63. PubMed ID: 18515281
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
[TBL] [Abstract][Full Text] [Related]
5. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
6. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Bloethner S; Chen B; Hemminki K; Müller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
Carcinogenesis; 2005 Jul; 26(7):1224-32. PubMed ID: 15760917
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
Kim YK; Ahn SK; Lee M
Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
[TBL] [Abstract][Full Text] [Related]
8. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
9. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
10. Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells.
Riedemann J; Sohail M; Macaulay VM
Biochem Biophys Res Commun; 2007 Apr; 355(3):700-6. PubMed ID: 17320820
[TBL] [Abstract][Full Text] [Related]
11. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53.
Niu J; Xu Z; Li XN; Han Z
Cell Biol Int; 2007 Feb; 31(2):156-64. PubMed ID: 17097318
[TBL] [Abstract][Full Text] [Related]
12. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
Wellbrock C; Marais R
J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
[TBL] [Abstract][Full Text] [Related]
13. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
14. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
15. B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.
Cui Y; Guadagno TM
Oncogene; 2008 May; 27(22):3122-33. PubMed ID: 18071315
[TBL] [Abstract][Full Text] [Related]
16. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
Christensen C; Guldberg P
Oncogene; 2005 Sep; 24(41):6292-302. PubMed ID: 16007203
[TBL] [Abstract][Full Text] [Related]
17. Is B-Raf a good therapeutic target for melanoma and other malignancies?
Madhunapantula SV; Robertson GP
Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
[TBL] [Abstract][Full Text] [Related]
18. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
Chetoui N; Sylla K; Gagnon-Houde JV; Alcaide-Loridan C; Charron D; Al-Daccak R; Aoudjit F
Mol Cancer Res; 2008 Jan; 6(1):42-52. PubMed ID: 18234961
[TBL] [Abstract][Full Text] [Related]
20. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]